The role of mitochondria-associated reactive oxygen species in the amyloid β induced production of angiogenic factors by ARPE-19 cells

Current Molecular Medicine

Volumn 17, Issue 2, 2017, Pages 140-148

  Wu, L ^a   Tan, X ^a   Liang, L ^a   Yu, H ^a   Wang, C ^a   Zhang, D ^a   Kijlstra, A ^b   Yang, P ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Age related macular degeneration; Amyloid ; Choroidal neovascularization; Drusen; Mitochondria associated reactive oxygen species; Retinal pigment epithelium

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; ANGIOGENIC FACTOR; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTRALIZING ANTIBODY; REACTIVE OXYGEN METABOLITE; VASCULOTROPIN; VISUAL PIGMENT; AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; VASCULOTROPIN A;

AGE RELATED MACULAR DEGENERATION; ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DRUSEN; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIAL CELL LINE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MITOCHONDRION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RETINAL PIGMENT EPITHELIUM; SUBRETINAL NEOVASCULARIZATION; CELL CULTURE; CELL LINE; GENETICS; IMMUNOLOGY; METABOLISM;

AMYLOID BETA-PEPTIDES; ANGIOGENESIS INDUCING AGENTS; BIOMARKERS; CELL LINE; CELLS, CULTURED; CHEMOKINE CCL2; COMPLEMENT C3A; COMPLEMENT C5A; HUMANS; INTERLEUKIN-8; MITOCHONDRIA; REACTIVE OXYGEN SPECIES; RETINAL PIGMENT EPITHELIUM; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 85022208544     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/1566524017666170331162616     Document Type: Article

References (46)

1. Gohdes DM, Balamurugan A, Larsen BA, Maylahn C. Age-related eye diseases: an emerging challenge for public health professionals. Prev Chronic Dis 2005; 2: A17.
2. Congdon NG, Friedman DS, Lietman T. Important causes of visual impairment in the world today. JAMA 2003; 290: 2057-60.
3. Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. Lancet 2012; 379: 1728-38.
4. Klein R, Chou CF, Klein BE, Zhang X, Meuer SM, Saaddine JB. Prevalence of age-related macular degeneration in the US population. Arch Ophthalmol 2011; 129: 75-80.
5. Chou CF, Cotch MF, Vitale S, et al. Age-related eye diseases and visual impairment among U.S. adults. Am J Prev Med 2013; 45: 29-35.
6. Maberley DA, Hollands H, Chuo J, et al. The prevalence of low vision and blindness in Canada. Eye (Lond) 2006; 20: 341-6.
7. Jonasson F, Arnarsson A, Eiriksdottir G, et al. Prevalence of age-related macular degeneration in old persons: Age, Gene/environment Susceptibility Reykjavik Study. Ophthalmology 2011; 118: 825-30.
8. Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 2004; 122: 598-614.
9. Nowak JZ. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep 2006; 58: 353-63.
10. Spilsbury K, Garrett KL, Shen WY, Constable IJ, Rakoczy PE. Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am J Pathol 2000; 157: 135-44.
11. Abdelsalam A, Del Priore L, Zarbin MA. Drusen in age-related macular degeneration: pathogenesis, natural course, and laser photocoagulation-induced regression. Surv Ophthalmol 1999; 44: 1-29.
12. Johnson PT, Lewis GP, Talaga KC, et al. Drusen-associated degeneration in the retina. Invest Ophthalmol Vis Sci 2003; 44: 4481-8.
13. Pauleikhoff D. [Drusen in Bruch's membrane. Their significance for the pathogenesis and therapy of age-associated macular degeneration]. Ophthalmologe 1992; 89: 363-86.
14. Luibl V, Isas JM, Kayed R, Glabe CG, Langen R, Chen J. Drusen deposits associated with aging and age-related macular degeneration contain nonfibrillar amyloid oligomers. J Clin Invest 2006; 116: 378-85.
15. Bressler SB, Maguire MG, Bressler NM, Fine SL. Relationship of drusen and abnormalities of the retinal pigment epithelium to the prognosis of neovascular macular degeneration. The Macular Photocoagulation Study Group. Arch Ophthalmol 1990; 108: 1442-7.
16. Yoshida T, Ohno-Matsui K, Ichinose S, et al. The potential role of amyloid beta in the pathogenesis of age-related macular degeneration. J Clin Invest 2005; 115: 2793-800.
17. Nozaki M, Raisler BJ, Sakurai E, et al. Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci U S A 2006; 103: 2328-33.
18. Dentchev T, Milam AH, Lee VM, Trojanowski JQ, Dunaief JL. Amyloid-beta is found in drusen from some age-related macular degeneration retinas, but not in drusen from normal retinas. Mol Vis 2003; 9: 184-90.
19. Anderson DH, Talaga KC, Rivest AJ, Barron E, Hageman GS, Johnson LV. Characterization of beta amyloid assemblies in drusen: the deposits associated with aging and age-related macular degeneration. Exp Eye Res 2004; 78: 243-56.
20. Baffi J, Byrnes G, Chan CC, Csaky KG. Choroidal neovascularization in the rat induced by adenovirus mediated expression of vascular endothelial growth factor. Invest Ophthalmol Vis Sci 2000; 41: 3582-9.
21. Ferrara N, Gerber H-P, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-76.
22. Frank RN, Amin RH, Eliott D, Puklin JE, Abrams GW. Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am J Ophthalmol 1996; 122: 393-403.
23. Kurji KH, Cui JZ, Lin T, et al. Microarray analysis identifies changes in inflammatory gene expression in response to amyloid-β stimulation of cultured human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 2010; 51: 1151-63.
24. Wang J, Ohno-Matsui K, Yoshida T, et al. Amyloid-beta up-regulates complement factor B in retinal pigment epithelial cells through cytokines released from recruited macrophages/microglia: Another mechanism of complement activation in age-related macular degeneration. J Cell Physiol 2009; 220: 119-28.
25. Li A, Dubey S, Varney ML, Dave BJ, Singh RK. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 2003; 170: 3369-76.
26. Niu J, Azfer A, Zhelyabovska O, Fatma S, Kolattukudy PE. Monocyte chemotactic protein (MCP)-1 promotes angiogenesis via a novel transcription factor, MCP-1-induced protein (MCPIP). J Biol Chem 2008; 283: 14542-51.
27. Charo IF, Taubman MB. Chemokines in the pathogenesis of vascular disease. Circ Res 2004; 95: 858-66.
28. Strieter RM, Polverini PJ, Arenberg DA, Kunkel SL. The role of CXC chemokines as regulators of angiogenesis. Shock 1995;4:155-60.
29. Belperio JA, Keane MP, Arenberg DA, et al. CXC chemokines in angiogenesis. J Leukoc Biol 2000; 68: 1-8.
30. Salcedo R, Ponce ML, Young HA, et al. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 2000; 96: 34-40.
31. Bruban J, Glotin AL, Dinet V, et al. Amyloid-beta(1-42) alters structure and function of retinal pigmented epithelial cells. Aging Cell 2009; 8: 162-77.
32. Kim YW, West XZ, Byzova TV. Inflammation and oxidative stress in angiogenesis and vascular disease. J Mol Med (Berl) 2013; 91: 323-8.
33. Ushio-Fukai M, Alexander RW. Reactive oxygen species as mediators of angiogenesis signaling. Role of NAD (P) H oxidase. Mol Cell Biochem 2004; 264: 85-97.
34. Johnson LV, Ozaki S, Staples MK, Erickson PA, Anderson DH. A potential role for immune complex pathogenesis in drusen formation. Exp Eye Res 2000; 70: 441-9.
35. Mastellos D, Andronis C, Persidis A, Lambris JD. Novel biological networks modulated by complement. Clin Immunol 2005; 115: 225-35.
36. Wang Q, Qi J, Hu R, Chen Y, Kijlstra A, Yang P. Effect of berberine on proinflammatory cytokine production by ARPE-19 cells following stimulation with tumor necrosis factor-α. Invest Ophthalmol Vis Sci 2012; 53: 2395-402.
37. Fukuoka Y, Medof ME. C5a receptor-mediated production of IL-8 by the human retinal pigment epithelial cell line, ARPE-19. Curr Eye Res 2001; 23: 320-5.
38. Fukuoka Y, Strainic M, Medof M. Differential cytokine expression of human retinal pigment epithelial cells in response to stimulation by C5a. Clin Exp Immunol 2003; 131: 248-53.
39. Cortright DN, Meade R, Waters SM, Chenard BL, Krause JE. C5a, but not C3a, increases VEGF secretion in ARPE-19 human retinal pigment epithelial cells. Curr Eye Res 2009; 34: 57-61.
40. Chen M, Forrester JV, Xu H. Synthesis of complement factor H by retinal pigment epithelial cells is down-regulated by oxidized photoreceptor outer segments. Exp Eye Res 2007; 84: 635-45.
41. Gloire G, Legrand-Poels S, Piette J. NF-κB activation by reactive oxygen species: fifteen years later. Biochem Pharmacol 2006; 72: 1493-505.
42. Tak PP, Firestein GS. NF-κB: a key role in inflammatory diseases. J Clin Invest 2001; 107: 7-11.
43. Kiriakidis S, Andreakos E, Monaco C, Foxwell B, Feldmann M, Paleolog E. VEGF expression in human macrophages is NF-κB-dependent: studies using adenoviruses expressing the endogenous NF-κB inhibitor IκBα and a kinase-defective form of the IκB kinase 2. J Cell Sci 2003; 116: 665-74.
44. Ding JD, Lin J, Mace BE, Herrmann R, Sullivan P, Bowes Rickman C. Targeting age-related macular degeneration with Alzheimer’s disease based immunotherapies: anti-amyloid-β antibody attenuates pathologies in an age-related macular degeneration mouse model. Vision Res 2008; 48: 339-45.
45. Ding JD, Johnson LV, Herrmann R, et al. Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration. Proc Natl Acad Sci U S A 2011; 108: E279-87.
46. Catchpole I, Germaschewski V, Kam JH, et al. Systemic administration of Abeta mAb reduces retinal deposition of Abeta and activated complement C3 in age-related macular degeneration mouse model. PLoS One 2013; 8: e65518.